<DOC>
	<DOCNO>NCT00558155</DOCNO>
	<brief_summary>The aim study assess clinical effect immunostimulatory enteral parenteral nutrition patient undergoing resection gastrointestinal cancer . 205 subject randomly assign four study group , standard immunostimulating , enteral parenteral . The study design test hypothesis immunonutrition enteral nutrition would reduce incidence infectious complication follow upper gastrointestinal surgery .</brief_summary>
	<brief_title>The Impact Immunostimulating Nutrition Outcome Surgery</brief_title>
	<detailed_description>All patient qualify June 2001 December 2005 total distal subtotal gastrectomy pancreaticoduodenectomy screen eligibility participate study . Additional eligibility criterion include : age 18 80 year , Karnofsky performance status score 80 , adequate organ function measure routine blood test . Patients require preoperative nutritional support , well disseminated tumor , serious comorbidities ( American Society Anesthesiologists risk class 4 5 ) , renal liver failure exclude . The study design test hypothesis immunonutrition enteral nutrition would reduce incidence infectious complication follow upper gastrointestinal surgery . Therefore , patient randomly assign 2Ã—2 factorial design four group receive immunostimulating versus normal diet , enteral versus intravenous nutritional support . The secondary objective study evaluate effect nutritional intervention overall morbidity mortality rate , length hospital stay . After complete tumor resection , patient meet eligibility criterion intraoperatively assign either treatment group use sealed envelope contain computer-generated allocation number . The follow group generate : standard enteral nutrition ( SEN ) , immunostimulating enteral nutrition ( IMEN ) , standard parenteral nutrition ( SPN ) , immunostimulating parenteral nutrition ( IMPN ) . The study carry follow international ethical recommendation state Declaration Helsinki .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>resectable gastric pancreatic cancer age 18 80 year , Karnofsky performance status score 80 , adequate organ function unresectable gastric pancreatic cancer patient require preoperative nutritional support , disseminate tumor , serious comorbidities ( American Society Anesthesiologists risk class 4 5 ) , renal liver failure exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>immunonutrition</keyword>
	<keyword>enteral nutrition</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>surgery</keyword>
</DOC>